Manel Cascalló

Dr Cascalló has nearly 25 years of experience leading corporate strategy, partnering, scientific research, clinical development and intellectual property programs in the academia and the biotech industry. He is an expert in oncolytic therapies and gene therapy and its clinical development, a field in which has been involved from his PhD. Author of many original scientific papers and reviews in peer-reviewed journals, he is co-inventor of a significant number of patents on the use of adenovirus as antitumoral agents. He acted as researcher at the University of Barcelona (Spain), at the MD. Anderson Cancer Center de Houston (Houston, USA), at Merck Farma y Química (Barcelona, Spain), and at the Virotherapy Group of the Institut Català d'Oncologia (ICO) – IDIBELL. During his professional career Dr. Cascalló has always been focused on the development of new biotechnological agents for cancer treatment where he led different multidisciplinary teams. He possesses a solid expertise in Regulat